Oncology News Central Peer-Spectives

DREAMseq Trial: What It Means for Metastatic Melanoma Treatment

Sapna Patel, MD, Associate Professor at MD Anderson Cancer Center, and Robert Figlin, MD, Deputy Director at Cedars-Sinai Cancer, discuss the clinical implications of the DREAMseq trial, showing patients with BRAF-mutant metastatic melanoma live longer if they receive first-line ipilimumab plus nivolumab.

The Latest Thinking Regarding Adjuvant Pembrolizumab in Renal Cell Carcinoma Post-ASCO GU ‘22

Rana McKay, MD, Allan Pantuck, MD, and Robert Figlin, MD, discuss the recent update to the Keynote-564 study investigating adjuvant pembrolizumab in RCC and the impact on high-, medium-, and low-risk patients.  They also talk about the Disease-Free Survival (DFS) endpoint, discussing the study with patients, and the recent NCCN guidelines update.

Post ASCO GU ’22 – Muscle-Invasive Bladder Cancer, EV-103, Enfortumab Vedotin, and the Clinical Progress Being Made Managing MIBC Patients

Daniel Petrylak, MD, Professor of Medicine at the Yale Cancer Center, and Robert Figlin, MD, of Cedars-Sinai Cancer discuss recent developments at ASCO GU in muscle-invasive bladder cancer and in particular the EV-103 clinical study while also discussing the future of MIBC treatment.

The HIMALAYA Study Presented at ASCO GI ’22: An Update on the State of Liver Cancer Treatment Today

Ghassan Abou-Alfa, MD and Robert Figlin, MD, discuss the presentation of the HIMLAYA clinical study at ASCO GI ’22 and how this regimen may fit in the liver cancer treatment landscape

Frederick Locke, MD of Moffit Cancer Center and Robert Figlin, MD of Cedars-Sinai discuss ZUMA-7, the role of CAR-T in the management of relapsed/refr...

Frederick Locke, MD and Robert Figlin, MD discuss ZUMA-7 and when to start thinking about integrating CAR-T into B-cell lymphoma treatment algorithms, the role of BMT in these patients, and how recent data presented at ASH ’21 shows that CAR-T cell therapies can work well in relapsed/refractory B-cell lymphoma.

From SABCS ’21: Neoadjuvant Immunotherapy and the Use of the 21-Gene Signature Test

Lajos Pusztai, MD, and Robert Figlin, MD, discuss the practicality of neoadjuvant I-O as demonstrated in KEYNOTE-522 and the application of the Oncotype DX 21-gene signature test in the RxPONDER study, both presented at the 2021 San Antonio Breast Cancer Symposium.

Targeted Therapy and Venclexta Combinations for AML and a Look Ahead to ASH ’21

Naval Daver, MD, and Robert Figlin, MD, discuss FLT3, TP53, and venetoclax combinations in the management of AML patients and what to look forward to at ASH 2021.  

After CodeBreaK100:

Kathryn Arbour, MD, joins host Robert Figlin, MD, to discuss the importance of the KRAS-targeted drug, sotorasib, in the treatment of non-small cell lung cancer. Kathryn Arbour, MD, joins host Robert Figlin, MD, to discuss the role next-generation sequencing plays in lung cancer care, the responses seen with the KRAS-targeted drug, sotorasib, in CodeBreaK100, and what optimal use of the drug will look like down the road.

ESMO ’21: The ARCHES Study and Progress in Metastatic (and Non-Metastatic) Hormone-Sensitive Prostate Cancer

Andrew Armstrong, MD and Robert Figlin, MD discuss the ARCHES study investigating the role of enzalutamide in metastatic hormone-sensitive prostate cancer, followed by a discussion of the latest treatment trends in non-metastatic hormone-sensitive prostate cancer.

Recent Clinical Progress in Ovarian Cancer

Robert Coleman, MD and Robert Figlin, MD, discuss the evolving role of bevacizumab in ovarian cancer, recently presented clinical studies such as BOOST and EFFORT, and the challenge of treating the PARP-refractory setting in advanced ovarian cancer.